Pórszász, RóbertYoshikawa, Takahide2026-04-152026-04-152025-11-18https://hdl.handle.net/2437/406247Bronchial asthma is a chronic inflammatory airway disease characterized by variable symptoms and reversible airflow limitation. In recent years, biologic therapies have emerged as an important treatment option, particularly for patients with severe or therapy-resistant asthma. The aim of this thesis was to review current pharmacological treatment strategies for asthma, with a focus on the clinical role and effectiveness of biologic therapy. The review was based on international clinical guidelines and recent randomized controlled trials published between 2018 and 2025. Biologic agents targeting IgE, IL-5, IL-4 receptor, and TSLP have shown significant reductions in exacerbation rates, oral corticosteroid dependence, and symptom burden in selected patient populations. Treatment response appears to correlate with biomarkers such as blood eosinophil count, IgE levels, and fractional exhaled nitric oxide (FeNO). In conclusion, biologic therapy represents a major advancement in asthma management. Appropriate patient selection and a biomarker-guided approach are key to achieving optimal outcomes.43enasthma, biologics, bronchial asthmaMedicineHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.